J&J’s IL-23 star guselkum­ab grabs the spot­light in PhI­II pso­ri­a­sis show­down

J&J has long had high hopes for its an­ti-in­flam­ma­to­ry IL-23 drug guselkum­ab. And to­day in Vi­en­na they de­tailed the first round of Phase III da­ta for se­vere plaque pso­ri­a­sis that ex­plains why.

In­ves­ti­ga­tors say this drug not on­ly hand­i­ly beat a place­bo, it al­so out­stripped the megablock­buster Hu­mi­ra in key mea­sures of ef­fi­ca­cy. And that will help po­si­tion the phar­ma gi­ant as it starts to line up reg­u­la­to­ry ap­provals for a new ther­a­py that’s like­ly head­ed in­to a heav­i­ly com­pet­i­tive mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER